ArticleFrontiers in public health2022

Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China.

Taihang Shao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.